Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.

“Linda is a demonstrated leader who has driven research success through team building, clinical strategy and execution at all phases of drug development,” said Daniel Swisher, Chief Executive Officer of Sunesis. “Her insights and experience are welcome additions to the team as we look to advance vosaroxin to European marketing approval, and accelerate the development of our kinase inhibitor pipeline, including our unique non-covalently binding BTK inhibitor, SNS-062.”

“I was drawn to this opportunity by the depth and potential of Sunesis’ pipeline,” stated Dr. Neuman. “Each of our clinical assets has the potential to address significant areas of unmet medical need in the treatment of cancer.  I look forward to working with Sunesis’ entrepreneurial team to advance these programs to the market.”

At Puma Biotechnology, Dr. Neuman contributed to the development strategy for neratinib, a tyrosine kinase inhibitor under investigation for the treatment of breast cancer and other solid tumors. Prior to joining Puma in 2015, Dr. Neuman spent three years as Medical Director of Oncology at Onyx Pharmaceuticals, where she served as clinical lead on the global product development team, designing and implementing clinical development strategies on multiple development projects as well as interacting with regulators. Prior to joining Onyx, Dr. Neuman held roles of increasing responsibility at Covidien Pharmaceuticals, Millennium Pharmaceuticals and Schering-Plough.

Dr. Neuman obtained her medical degree from Southern Illinois University, where she also received her Bachelor of Science in biology. Dr. Neuman also holds a Master in Business Administration fromIndiana Wesleyan University.. (Original Source)

Shares of Sunesis Pharmaceuticals closed yesterday at $0.50, up $0.03 or 6.34%. SNSS has a 1-year high of $3.72 and a 1-year low of $0.44. The stock’s 50-day moving average is $0.51 and its 200-day moving average is $0.70.

On the ratings front, Cantor analyst Mara Goldstein reiterated a Buy rating on SNSS, in a report issued on May 5. According to, Goldstein has a yearly average return of -9.6%, a 40.1% success rate, and is ranked #3804 out of 3891 analysts.

Sunesis Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company primarily engages in development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The company’s primary activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital.